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In early stage (I and II) laryngeal squamous cell carcinoma, 
both surgery and radiotherapy results in significant local 
and regional control. In advanced tumors (III and IV), 
radiotherapy alone has local-regional control rates of 32-
43%. Aim: To assess disease-free survival in SCC laryngeal 
carcinoma patients submitted to radiotherapy alone and/or 
associated with chemotherapy. Materials and Methods: 
Retrospective study involving 84 cases of laryngeal SCC 
treated with radiotherapy or chemotherapy together with 
radiotherapy. Fifty-three cases were treated with intension 
to cure and 31 because of impossibility to resect the disease. 
As to clinical stage (CS), 12 were CS I, 15 II, 21 III and 5 
IV. In the second group, 11 cases were EC III and 20 IV. 
Results: Mean age was 60 years, 84.5% were men. Fifty-eight 
(69.1%) cases had complete response and 26 (30.9%) had 
persistent or residual disease. Five-year disease-free survival 
was of 42.5%; 62.5% of the patients with organ preservation 
indication and 9.75 in the group of irressecable disease. 
Conclusion: disease-free survival of those patients submitted 
to radiotherapy because of laryngeal SCC was of 62.5%
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INTRODUCTION
Patients with initial stage (I and II) laryngeal squa-
mous cell carcinoma benefit from surgery and radiothera-
py, showing significant rates of local and regional control 
and preserved speech, swallowing and breathing.1,2 The 
results in such early cases (stages I and II) are similar when 
using surgery or radiotherapy for local and regional con-
trol; rates are close to 100% for T1 tumors, and range from 
55% to 75% for T2 tumors. Radical surgery is an option 
if tumors persist after radiotherapy, as may happen more 
commonly with T2 tumors.
The assumption that voice quality - especially in 
T1 tumors - benefits more from radiotherapy than from 
surgery is not completely true. Often after radiotherapy 
permanent fibrosis of the lamina propria may develop, 
which compromises the ability of the vocal fold to vibra-
te because of its need to be whole for proper function. 
Acceptable recovery of voice, however, is possible in po-
orly infiltrated T1 tumors treated surgically (cordectomy); 
in this situation, scarring results in a similar structure to 
the vocal fold, which may even vibrate. Nevertheless, the 
literature shows that better results in voice quality are 
seen in patients submitted to organ-sparing protocols, 
compared to surgery.3
Local and regional control of advanced squamous 
cell carcinoma (III and IV) is achieved in 32% to 43% with 
radiotherapy.4,5 However, adjuvant surgery to radiothera-
py may significantly support local and regional control, 
particularly in patients with extensive primary tumors that 
involve the thyroid cartilage, soft tissues in the neck and 
the base of the tongue, and when there are metastases to 
neck lymph nodes.
The purpose of this study was to assess disease-free 
survival in patients with larynx squamous cell carcinoma 
undergoing conventional radiotherapy only or associated 
with chemotherapy.
SERIES AND METHOD
A retrospective analysis was made of 84 patients 
with larynx squamous cell carcinoma admitted from 
January 1999 to December 2004, first treated with con-
ventional radiotherapy. Inclusion criteria were previously 
untreated patients, where the indications for conventional 
radiotherapy were preservation of laryngeal function, re-
fusal of surgery, extension of the primary tumor requiring 
reconstruction of patients in poor clinical conditions, and 
non-resectability. The exclusion criterion was the presence 
of distance metastases upon admittance.
The anatomical site of the disease was the glottis in 
33 cases and the supraglottis in 49 cases. The anatomical 
site could not be defined in two cases because of extensive 
disease upon admittance.
Clinical staging was done according to the AJC-UICC 
(2002); there were 13 clinical stage I cases, 13 clinical stage 
II cases, 24 clinical stage III cases, and 34 clinical stage IV 
cases. The size of the primary tumor (T) and the presence 
of neck lymph nodes (N) were used to define two groups 
according to the indication of conventional radiotherapy: 
the first group consisted of patients that refused surgery 
and the candidates for preservation of laryngeal function; 
the second group comprised patients undergoing conven-
tional radiotherapy because of disease extension associated 
with a poor clinical status and non-resectability (Table 1).
Table 1. Distribution of cases according to the indication of conven-
tional radiotherapy and the clinical stage (TN).
Radiotherapy/ T N0 N1 N2 N3 Total
Organ preservation
*T1 12 2  0  0 14
 T2 13 0  2  0 15
 T3 12 7  3  0 22
 T4  2 0  0  0  2
 Total 39 9  5  0 53
Extension of tumor
 T1 0 0  0  0  0
 T2 0 0  2  4  6
 T3 2 3  4  3 12
 T4 4 1  5  3 13
 Total 6 4 11 10 31
n= 84 patients; * 10 T1a, one T1b, and three cases with the epicenter 
in the supraglottis.
Conventional radiotherapy was done with a linear 
accelerator at a mean dose of 66.7 Gy (19 Gy to 74 Gy). 
The concomitant chemotherapy protocol recommends 
starting therapy on the tenth radiotherapy session with six 
cycles of cisplatin (CDDP) at 25 to 30 mg/m2/weekly. We 
indicate one to three cycles of cisplatin (CDDP) at 100 mg/
m2 if neoadjuvant chemotherapy is initiated; in this case, 
a third of the dose is given in the first three days (D1, 2, 
3), 450 mg/m2 (D1-5) 5-fluorouracil (5FU) and 135 mg/
m2 (D1) paclitaxel.
The definition of local and regional control was 
absence of evidence of disease six months after the end 
of treatment. Persistence was considered as evidence of 
disease within the first six months after the end of treat-
ment. Response to therapy was considered as the absence 
of evident lesions in the local and regional examination 
within 30 days after the end of radiotherapy.
The Kaplan Meier method was applied to study 
survival rates, and the Wilcoxon method was applied to 
investigate differences in survival. Patients that refused sur-
gery were considered as candidates for organ preservation 
in the survival curves. The institutional review board of 
our institution approved this study (number 659).
227
Brazilian Journal of otorhinolaryngology 76 (2) March/april 2010
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
RESULTS
The mean follow-up of patients was 28.9 months; 10 
patients (11.9%) were lost to outpatient follow-up within 
the study period. There were 74 male patients (84.5%) and 
13 female patients (15.5%); the mean age was 60 years 
(37 to 78 years).
Fifty-four patients (64.3%) underwent radiotherapy 
exclusively, 24 patients (28.6%) underwent chemotherapy 
plus radiotherapy, and six patients (7.1%) underwent neo-
adjuvant chemotherapy plus chemoradiotherapy.
Conventional radiotherapy below 40 Gy was inter-
rupted in four patients. In three cases this was because 
their clinical status worsened; a fourth patient abandoned 
therapy. At the end of radiotherapy, full local and regional 
response was observed in 58 patients (69.1%); the disease 
persisted in 26 patients (30.9%). These cases were distribu-
ted according to the epicenter of the tumor (in the glottis or 
supraglottis) where radiotherapy was indicated (Table 2).
Table 2. Distribution of the response to conventional radiotherapy, 
the tumor site and the indication for radiotherapy.
Site*/Radiotherapy Control Persistence Total
Glottis
Preservation 17  7 27
Extension  2  7  9
Total 19 14 33
Supraglottis
Preservation 25  4 29
Extension 12  8 20
Total 37 12 49
n= 82 patients; * two cases of extensive tumors, both with their tumors 
controlled at the end of radiotherapy
Table 3 shows the type of disease persistence (lo-
cal, regional or local and regional) at the end of therapy 
(Table 3).
The global survival rate among 84 patients was 
47.5%; the 5-year disease free survival rate was 42.5%. The 
5-year disease-free survival rate according to the indication 
of radiotherapy was 62.5% in organ preservation cases; it 
was 9.75% in patients irradiated due to disease extension 
or non-resectability (Charts 1 and 2).
Early tumors (T1 and T2) and advanced cases (T3 
and T4) were grouped, as seen below, to calculate disease-
free survival in patients irradiated according to the size of 
the primary tumor (Chart 3).
The 5-year control rates of primary tumors (T) were 
84% (T1), 44% (T2), 37% (T3) and zero (T4).
The 5-year disease-free survival was 38% in patients 
undergoing radiotherapy only, 49% when chemotherapy 
was added, and 45% in cases with induction chemothera-
py for chemoradiotherapy (p=0.1). Seven clinical stage II 
tumor cases underwent radiotherapy only, and six such 
Table 3. Distribution of the type of persistence at the end of radiothe-








Preservation 7 0 0
Extension 6 0 1
Supraglottis
Preservation 2 2 0
Extension 3 2 3
n= 26 patients.
Chart 1. Distribution of global survival. - n=84 patients
Chart 2. Distribution of disease-free survival according to the indi-
cation of - n= 84 patients, of which 53 underwent radiotherapy with 
preservation of the larynx, and 31 because of tumor extension or 
non-resectability.
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cases underwent chemoradiotherapy. Thirty-five patients 
in clinical stages III and IV underwent radiotherapy only; 
chemotherapy (concomitant) was added to the treatment 
of 24 such patients. Assessing concomitant chemotherapy 
in clinical stages II, III and IV and the type of indication 
of radiotherapy showed that therapy was indicated in 
8/31 patients (25.8%) because of tumor extension or non-
resectability, and in 21/40 patients (52.5%) due to organ 
preservation.
Twenty-six patients had persistent or residual di-
sease at the end of radiotherapy; 18 of these were local, 
4 were regional, and 4 were local and regional. Four of 
these patients underwent salvage surgery of the primary 
tumor - two subtotal laryngectomies with CHEP. In both 
case, lesions were previously T1 and T2. The other two 
patients underwent salvage surgery at another institution; 
one was a fronto-lateral laryngectomy (previously T1a) 
and the other was a total laryngectomy (previously T2).
There were 21 cases of local and regional recur-
rences; 10 were exclusively local, five were exclusively 
regional, five were local and regional, and one was local 
with a distance metastasis. Six patients underwent salvage 
surgery for treatment of the primary tumor - either total 
laryngectomy or pharyngolaryngectomy. Two of these 
cases were previously T1 lesions; the remaining cases 
were T3. Salvage neck dissection was carried out in two 
patients that had clinically metastatic lymph nodes on the 
first visit. Two patients refused salvage surgery.
Six patients had distance metastases; the lung was 
the site in all cases. Three cases presented a second primary 
tumor - two in the head and the neck.
By the last outpatient visit within the study period 
29 patients had died because of the disease, 18 were 
alive but with local and regional disease and/or distance 
metastases, 5 had died due to other causes and 32 were 
alive with local, regional and distance control.
DISCUSSION
Conventional radiotherapy aims to preserve laryn-
geal function in the treatment of early tumors (T1 and T2), 
similarly to partial surgery. However, the results are worse 
for local and regional control of advanced tumors (T3 and 
T4), especially if there are large lymph node metastases.6
Goepfert et al.7 showed that the results of radiothe-
rapy are similar to those of surgery for supraglottic lesions 
that can be removed with partial laryngectomy; ranging 
from 88.5% for T1 lesions to 60% for T4 lesions. The M.D. 
Anderson Cancer Center, Houston (Texas), also demons-
trated satisfactory results for local control of the disease 
in stages T1, T2 and selected T3 cases. In the beginning 
of the 1990s, local disease control rates were 100% (T1), 
81% (T2), and 61% (T3) when using hyperfractionated 
radiotherapy.8
In the literature, local control of T1 glottic lesions 
reaches over 90%, varying according to involvement of one 
or both vocal folds.9,10 Thus, local control is decreased in 
lesions that involve the anterior commissure (92.3% 5-year 
disease-free survival rate) compared to lesions only in one 
vocal fold (85% 5-year disease-free survival rate).10
The 5-year local control rate among our T1 tumor 
cases was 84%. There were two cases in which the disease 
persisted after radiotherapy; these T1a lesions were treated 
with fronto-lateral laryngectomy and subtotal laryngectomy 
with CHEP. Local recurrence was diagnosed in three cases; 
all were glottic lesions, one of which was previously T1b. 
Two cases underwent total laryngectomy.
Local control of glottic T2 tumors with conventional 
radiotherapy ranged from 55% to 76%; this is lower than 
surgery as the first approach.1,2 A factor for poorer results 
in irradiated T2 tumors was the presence of vocal fold 
mobility; if there is mobility, local control rates are higher 
than 70%. On the other hand, radiotherapy is drastically 
less effective for lesions associated with decreased vocal 
fold mobility; a return to normal mobility after therapy is 
an independent prognostic factor regardless of the num-
ber of local recurrences.11 Other factors associated with 
a poorer prognosis is disease extension to the subglottis 
and the piriform recess.2 A published series has shown 
that the presence of an intermediate signal on the thyroid 
cartilage of patients with T2 tumors in magnetic resonance 
imaging highly suggested invasion of the thyroid cartilage 
and a worse prognosis.12
The main factor associated with a complete respon-
se to radiotherapy in supraglottic T2 tumors was tumor 
volume; best results are seen in superficial and lower 
volume tumors. Studies at Florida University have shown 
that local control was attained in 83% of tumors smaller 
Chart 3. Distribution of disease-free survival according to the size of -
n=84 patients, of which 35 with early tumors (T1 and T2), and 49 with 
advanced tumors (T3 and T4).
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than 6 cm3 as measured in computed tomography or mag-
netic resonance imaging. Local control was 46% in tumors 
larger than 6 cm3.13
In our study, 5-year local control of T2 tumors tre-
ated with conventional radiotherapy was lower compared 
to the literature. No association was seen with extension 
to neighboring sub-sites or decreased vocal fold mobility 
at the point when radiotherapy was indicated. However, 
the mean waiting time between the initial clinical visit 
and radiotherapy was 60 days (the distance between the 
radiotherapy center and the outpatient unit was often a 
difficulty for patients), which could result in disease pro-
gression and vocal fold paralysis, which would redefine 
the lesion as a T3 tumor at the beginning of therapy.
There were five cases of disease persistence at the 
end of conventional radiotherapy; two of these patients 
underwent salvage surgery (total laryngectomy and sub-
total laryngectomy with CHEP. One in three cases of local 
recurrences underwent total salvage laryngectomy.
Local control of T3 tumors is poorer compared to 
initial surgery in advanced laryngeal tumors (III and IV), 
about 30% to 40%, and similar to our results.4,14 Harwood 
et al.15 showed that among radiotherapy-treated T3 le-
sions, worse results were seen in transglottic tumors. If 
transglottic tumors are excluded from our series, the local 
control rate reaches about 50%. Using hyperfractionated 
radiotherapy, the phase II ARCON study (accelerated 
radiotherapy, carbogen, nicotinamide) of 100 patients 
with advanced laryngeal tumors (T3 and T4) showed that 
3-year local control was 80%.16 An issue is that T4 tumors 
extending to the muscles of the tongue base, soft tissues 
of the neck and major destruction of the thyroid cartilage 
were excluded. These factors probably account for decre-
ased local control by radiotherapy in T4 tumors, because 
the indicated treatment is combined therapy (surgery and 
postoperative radiotherapy or radiotherapy and surgery); 
furthermore, most of these patients require tracheotomy 
and/or enteric tubes at the beginning of therapy.
In the present study, no persisting cases underwent 
salvage therapy; of seven local recurrences, four patients 
underwent total salvage laryngectomy. A disadvantage of 
radiotherapy in laryngeal T3 tumors is that it is harder to 
preserve function when indicating salvage surgery, es-
pecially in cases that previously would have undergone 
subtotal laryngectomy. In such cases, the best initial choice 
is subtotal laryngectomy. A further issue is the difficulty to 
diagnose local disease persistence on histology because 
of the side effects of radiotherapy - marked edema com-
monly seen in these patients, and necrosis of the thyroid 
cartilage, both of which delay salvage therapy. This factor 
may also be associated with disease progression and a 
poorer clinical status, making the disease non-resectable 
and/or inoperable.
On the other hand, supracricoid laryngectomy with 
CHEP as the initial therapy may lead to loss of function, 
such as aspiration and absence of decanulation. Chevalier 
et al.17 presented a 112-case series of laryngeal tumors ini-
tially treated with supracricoid laryngectomy with CHEP; 
22 of these tumors were T3 stage. Two patients required 
a permanent tracheotomy postoperatively because of la-
ryngeal stenosis, and underwent total laryngectomy.
Cases where subtotal laryngectomy with CHEP is 
indicated for T2 and T3 tumors, regardless of the neck 
lymph node status, surgery is the procedure of choice at 
our unit. Especially in T3 tumors, the prognosis of subtotal 
laryngectomy is comparable to total laryngectomy, with 
excellent functional results in most patients. Our institu-
tional guidelines prioritize laryngectomy for the treatment 
of T3 tumors, even if the neck is N(0) and radiotherapy is 
offered as an alternative therapy.
In the early 1990s, the results of the Veterans Affairs 
Laryngeal Cancer Study Group showed that 38% were 
total laryngectomies in patients undergoing chemoradio-
therapy; 56% were T4 tumors. The rate of salvage surgery 
was below 29% in tumors below stage T4.18 In that study, 
four patients with T4 tumors responded completely to 
conventional radiotherapy and did not require salvage 
surgery when there were local recurrences. However, 
most of the cases undergoing conventional radiotherapy 
were thus treated because the tumors were non-resectable 
or the disease was extensive and associated with poor 
clinical conditions. This scenario differs from some organ 
preservation protocols with resectable T4 disease, and 
those patients with lesions massively involving the thyroid 
cartilage and extending to soft tissues of the neck, which 
appear to respond better to surgery as the initial treatment; 
in such cases, preserving laryngeal function is uncommon 
in the patients at our unit.
Forastiere et al.19 showed that clinical stage II, II 
and IV patients undergoing chemoradiotherapy (78%) 
and induction chemotherapy (61%) had a higher rate of 
local and regional disease control compared to patients 
undergoing ionizing radiation alone (56%). Associating 
chemotherapy with radiotherapy undoubtedly yields 
superior local and regional control of the disease, which 
concurs with our findings in the present study. A higher 
number of indications for conventional radiotherapy alone 
are due to non-resectable tumors, extensive disease and 
organ preservation in early tumors (T1 and T2) with no 
palpable lymph nodes.
Among the indications of conventional radiotherapy 
in cases where regional disease persisted at the end of ra-
diotherapy, no cases required neck dissection in our study. 
All patients had palpable neck lymph nodes (clinical stage 
N3) and/or non-resectable tumors that contraindicated 
initial salvage surgery.
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CONCLUSIONS
In this study of patients with larynx squamous cell 
carcinoma, in which conventional radiotherapy associated 
or not with chemotherapy was given, about 63.1% of cases 
with resectable disease and an indication for preserving 
organs had a 62.5% 5-year disease-free survival rate.
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